We are live on ! Find out more
SNOA icon

Sonoma Pharmaceuticals

20 hedge funds and large institutions have $1.56M invested in Sonoma Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

386% more capital inflows, than outflows

Capital inflows: $347K | Capital outflows: $71.3K

18% more funds holding

Funds holding: 17 → 20 (+3)

1.69% more ownership

Funds ownership: 8.52% → 10.21% (+1.7%)

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

Holders
20
Holders Change
+3
Holders Change %
+17.65%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
6
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

SNOA Hedge Fund Activity: Q2 2021 in Review

20 of the 5,771 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q2 2021, worth a combined $1.56M — up 18% from $1.32M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new SNOA positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 6 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $237K. The largest seller was Renaissance Technologies, cutting an estimated $52.3K.

  • 20 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q2 2021, up from 17 in Q1 2021.
  • Funds reported $1.56M of Sonoma Pharmaceuticals stock for Q2 2021, up 18% quarter-over-quarter.
  • 3 funds opened new Sonoma Pharmaceuticals positions in Q2 2021 and 0 closed out, a net change of +3 holders.
  • The largest Sonoma Pharmaceuticals buyer in Q2 2021 was Geode Capital Management, an estimated $237K added.
  • The largest Sonoma Pharmaceuticals seller in Q2 2021 was Renaissance Technologies, an estimated $52.3K sold.

Based on aggregated 13F filings for Q2 2021.